PT  - JOURNAL ARTICLE
AU  - Clancy, Jeffrey
AU  - Hoffmann, Curtis S.
AU  - Pickett, Brett E.
TI  - Transcriptomics Meta-Analysis Predicts Two Robust Human Biomarkers for Severe Infection with SARS-CoV-2
AID  - 10.1101/2022.06.06.22276040
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.06.22276040
4099  - http://medrxiv.org/content/early/2022/06/06/2022.06.06.22276040.short
4100  - http://medrxiv.org/content/early/2022/06/06/2022.06.06.22276040.full
AB  - Defining the human factors associated with severe vs mild SARS-CoV-2 infection has become of increasing interest. Mining large numbers of public gene expression datasets is an effective way to identify genes that contribute to a given phenotype. Combining RNA-sequencing data with the associated clinical metadata describing disease severity can enable earlier identification of patients who are at higher risk of developing severe COVID-19 disease. We consequently identified 358 public RNA-seq human transcriptome samples from the Gene Expression Omnibus database that had disease severity metadata. We then subjected these samples to a robust RNA-seq data processing workflow to quantify gene expression in each patient. This process involved using Salmon to map the reads to the reference transcriptomes, edgeR to calculate significant differential expression levels, and gene ontology enrichment using Camera. We then applied a machine learning algorithm to the read counts data to identify features that best differentiated samples based on COVID-19 severity phenotype. Ultimately, we produced a ranked list of genes based on their Gini importance values that includes GIMAP7 and S1PR2, which are associated with immunity and inflammation (respectively). Our results show that these two genes can potentially predict people with severe COVID-19 at up to ∼90% accuracy. We expect that our findings can help contribute to the development of improved prognostics for severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only publicly available, de-identified data were included in our analysis, so no IRB approval is required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly available RNA-seq fastq files were obtained from the NCBI Gene Expression Omnibus. The relevant studies include: GSE152418, GSE157103, and GSE166424. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152418 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157103 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166424